AIOSYN
9.5.2023 11:03:35 CEST | Business Wire | Press release
Aiosyn, a medical software company that develops AI-powered pathology solutions, has been awarded a EUR 1.300.000 EFRO-OOST grant alongside Radboud university medical center and Pathologie-DNA to accelerate the development of AI technology for breast and skin cancer diagnostics. With the AIRAT project, the three organizations will join forces to introduce CE-marked deep learning algorithms for automated mitosis detection to the market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230508005736/en/
Mitotic figures (cells that are in the process of dividing) are identified and highlighted with Aiosyn's algorithm for automated mitosis detection. (Photo: Business Wire)
Wouter Bulten, Chief innovation officer of Aiosyn: “At Aiosyn, we recognize the critical role pathologists play in diagnostics. Through close collaboration, this EFRO grant enables us to further develop AI tools that support pathologists and enhance pathology practice.”
Close to 20 million patients are diagnosed with cancer every year1. Unfortunately, incidence is expected to increase in the upcoming decades, with a predicted global burden of about 30 million new cancer cases per year by 20402. This underlines the need for new tools to improve the efficiency and accuracy of the disease diagnosis and treatment.
As part of this project, Aiosyn will further develop and validate AI-powered algorithms for breast and skin cancer diagnosis. One of such algorithms is Aiosyn’s solution for automated mitosis detection. The quantification of mitotic figures in cancer tissue is an essential part of the diagnosis of multiple tumor types. By leveraging AI-based digital biomarkers, pathologists can more accurately predict tumor growth and understand patient prognosis. This will help reduce observer variability, improve the accuracy and consistency of diagnoses, and ultimately enhance patient outcomes.
Jeroen van der Laak, professor at Radboud university medical center and CSO of Aiosyn: “Once you have decided which problem to solve, and have collected all required data, developing AI for Pathology is doable. But collecting high-quality data is tough, and getting the AI to a level that truly creates patient value is even tougher. In our AIRAT project we will tackle those challenges: collect multi-center data and move the developed AI forward to a certified product, ready to support pathologists.”
Aiosyn’s algorithms will be fully integrated in existing digital pathology workflows such as Sectra. The AI-powered solutions will aim to provide major progress in the assessment and disease management of cancer patients worldwide.
“We are excited to partner with Aiosyn and Radboud UMC on this project," said Matthijs van Oosterhout, on behalf of Pathologie-DNA, chairman of Pathologie-DNA B.V. "Together, we can leverage our respective strengths to develop AI solutions that will improve patient outcomes and advance the field of pathology. This collaboration is a great example of how start-ups and established companies can work together to drive innovation."
About Aiosyn
Aiosyn is a Dutch medical software company that develops AI-powered pathology solutions that will be integrated into standard pathology workflows. The Aiosyn team has been built upon 20+ years of research experience in the field of pathology and is rooted into the pathology practice.
About Radboud university medical center
Radboud university medical center is a university medical center for patient care, research, and education, located in Nijmegen. We mainly concentrate on prevention, meaningful and prudent healthcare, sustainability, artificial intelligence and data-driven systems, the molecular mechanisms of diseases and new treatments, and training the professionals of tomorrow.
About Pathologie-DNA
Pathologie-DNA is a collaboration between three pathology laboratories Jeroen Bosch Ziekenhuis, located in ‘s-Hertogenbosch, St. Antonius Ziekenhuis located in Nieuwegein and Rijnstate located in Arnhem. Pathologie-DNA is the partner in pathology for medical specialists, general practitioners and private diagnostic centres. We work with digital pathology. This makes it possible to provide continuous high-quality diagnostics. Consultation between colleagues and consultation with academic hospitals guarantee this quality.
Sources
1. World Cancer Day 2023: Close the care gap - PAHO/WHO | Pan American Health Organization
2. World Cancer Report: Cancer Research for Cancer Prevention (who.int)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005736/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software26.6.2026 23:28:00 CEST | Press release
Powered by the risk-centric PASTA methodology and two decades of accredited offensive security, the integrated platform lets enterprises threat model in a security sprint—then prove the risk through AI-led, human-on-the-loop testing. VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained s
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 22:30:00 CEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom